Treatment of hyperkalemia in patients with chronic kidney disease--a focus on medications.
Raymond
Colette B
CB
Winnipeg Regional Health Authority, Manitoba Renal Program, Winnipeg, MB. craymond@exchange.hsc.mb.ca
Sood
Amy R
AR
Wazny
Lori D
LD
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D002125:Calcium Gluconate / Q000627:therapeutic use; D002411:Cation Exchange Resins / Q000627:therapeutic use; D015984:Causality; D004232:Diuretics / Q000627:therapeutic use; D016903:Drug Monitoring; D004562:Electrocardiography; D005947:Glucose / Q000627:therapeutic use; D006801:Humans; D006947:Hyperkalemia / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D007328:Insulin / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications*; D009730:Nursing Assessment; D011188:Potassium / Q000097:blood; D017419:Potassium, Dietary / Q000009:adverse effects; D012720:Severity of Illness Index
D000318:Adrenergic beta-Agonists; D002411:Cation Exchange Resins; D004232:Diuretics; D007328:Insulin; D017419:Potassium, Dietary; D005947:Glucose; D011188:Potassium; D002125:Calcium Gluconate